Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | PPARA | Q07869 | 2/20 | 0.52 |
| ▸ | MAOB | P27338 | 4/20 | 0.50 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.50 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | PPARD | Q03181 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20954694 | 0.94 | MTNR1A (0.48) | L3MBTL1PPARAMAOBMTNR1AMTNR1B | |
| SCHEMBL20954700 | 0.93 | MTNR1A (0.58) | L3MBTL1PPARAMAOBMTNR1AMTNR1B | |
| SCHEMBL6247717 | 0.93 | MAOB (0.60) | L3MBTL1PPARAMAOBMTNR1AMTNR1B | |
| SCHEMBL20954710 | 0.91 | MTNR1A (0.47) | L3MBTL1PPARAMAOBMTNR1AMTNR1B | |
| SCHEMBL20954703 | 0.91 | MEN1 (0.51) | L3MBTL1PPARAMTNR1AMTNR1BNPC1 | |
| SCHEMBL8088656 | 0.89 | MRGPRX4 (0.47) | L3MBTL1PPARAMAOBMTNR1AMTNR1B | |
| SCHEMBL20954708 | 0.88 | MTNR1A (0.43) | L3MBTL1PPARAMTNR1AMTNR1B | |
| SCHEMBL13760599 | 0.86 | ALDH1A1 (0.51) | L3MBTL1MAOBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL10927781 | 0.86 | S1PR1 (0.57) | L3MBTL1PPARAMAOBNPC1RAB9A | |
| SCHEMBL3813849 | 0.86 | PTGER1 (0.54) | L3MBTL1MAOBSMN1; SMN2ALDH1A1ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070037874-A1 | Manufacturing process of isoflavan or isoflavene derivatives | BICBIO CO., LTD. (KR) | 2007-02-15 | — | — | US | disclosed |
| WO-2005037815-A1 | A MANUFACTURING PROCESS OF ISOFLAVAN OR ISOFLAVENE DERIVATIVES | BICBIO CO., LTD. (KR) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037874-A1 | Manufacturing process of isoflavan or isoflavene derivatives | CYP51A1, CYP2E1, CYP2F1 | L3MBTL1 4703/4885PPARA 1435/4885MAOB 701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.